GlassScriptPhysician profile
Isaac Sachmechi
NPI 1750340121
$349,092.37
in general payments reported to CMS, 2019-2025
71 companies · $79K in 2025
The $79K reported for 2025 was more than what 97% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $66K · 2020: $26K · 2021: $12K · 2022: $65K · 2023: $54K · 2024: $47K · 2025: $79K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $127K · Food and Beverage: $19K · Honoraria: $12K · Travel and Lodging: $10K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $7,425 · Consulting Fee: $3,728 · Education: $97.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $127,392.50 |
| Food and Beverage | $18,736.43 |
| Honoraria | $12,000.00 |
| Travel and Lodging | $10,279.09 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $7,425.00 |
| Consulting Fee | $3,728.00 |
| Education | $97.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $85,478.29 | 2019-2025 | Evenity, Tepezza, Prolia |
| Abbott Laboratories | $62,833.93 | 2019-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Janssen Pharmaceuticals, INC | $40,813.52 | 2019-2024 | Xarelto |
| Ascendis Pharma Endocrinology INC | $31,515.82 | 2023-2025 | Yorvipath |
| Intuity Medical INC | $25,610.40 | 2022-2023 | Pogo Automatic Blood Glucose Monitoring System |
| Chiesi USA, INC. | $22,507.44 | 2024-2025 | Mycapssa |
| Astrazeneca Pharmaceuticals LP | $19,844.07 | 2019-2024 | Lokelma, Farxiga |
| Shire North American Group INC | $14,910.65 | 2019 | |
| Merck Sharp & Dohme LLC | $8,111.23 | 2019-2025 | Capvaxive |
| Corcept Therapeutics | $7,073.69 | 2019-2025 | Korlym |
| Mannkind Corporation | $5,056.69 | 2019-2025 | Afrezza |
| Althera Pharmaceuticals LLC | $4,073.08 | 2021-2022 | |
| Ibsa Institut Biochimique Sa | $2,899.18 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $2,103.78 | 2019-2024 | Cycloset |
| Novo Nordisk INC | $1,865.37 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
Show all 68 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $1,755.52 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Ibsa Pharma INC. | $1,342.80 | 2022-2025 | Tirosint, Licart, Flector |
| Astrazeneca Uk Limited | $1,097.20 | 2019 | |
| Xeris Pharmaceuticals, INC. | $868.80 | 2020-2025 | Gvoke Hypopen, Recorlev |
| Sanofi-Aventis U.S. LLC | $849.73 | 2019-2024 | |
| Amneal Pharmaceuticals LLC | $780.70 | 2021-2025 | Unithroid |
| Alexion Pharmaceuticals, INC. | $650.84 | 2021-2025 | Strensiq |
| Horizon Therapeutics Plc | $630.85 | 2019-2023 | Tepezza |
| Radius Health, INC. | $614.57 | 2019-2024 | Tymlos |
| Vifor Pharma, INC. | $578.77 | 2019-2021 | |
| Pfizer INC. | $431.13 | 2020-2025 | |
| Novartis Pharmaceuticals Corporation | $402.34 | 2022-2025 | |
| Amryt Pharma Holdings LTD | $386.17 | 2022-2023 | Mycapssa |
| Insulet Corporation | $323.87 | 2019-2021 | |
| Madrigal Pharmaceuticals | $288.15 | 2024-2025 | Rezdiffra, Resmetirom |
| Zealand Pharma US, INC. | $261.44 | 2020-2021 | |
| Dexcom, INC. | $237.26 | 2021-2023 | Dexcom G6 Transmitter |
| Esperion Therapeutics, INC. | $231.77 | 2020-2025 | Nexletol |
| Tandem Diabetes Care, INC. | $219.40 | 2021-2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Janssen Scientific Affairs, LLC | $194.47 | 2022-2023 | Xarelto |
| Nevro Corp. | $158.39 | 2023 | Senza |
| Teva Pharmaceuticals USA, INC. | $158.34 | 2023-2025 | Austedo, Uzedy |
| Medtronic Minimed, INC. | $154.93 | 2019-2020 | |
| Medtronic, INC. | $133.37 | 2021-2024 | Minimed 780g |
| Abbvie INC. | $128.76 | 2019-2024 | Synthroid |
| E.R. Squibb & Sons, L.L.C. | $127.19 | 2019-2023 | Camzyos |
| Phathom Pharmaceuticals, INC. | $125.00 | 2025 | Voquezna |
| Progenics Pharmaceuticals, INC. | $125.00 | 2023 | Pylarify |
| Optinose US, INC. | $121.53 | 2021 | |
| Recordati_rare_diseases_inc. | $95.92 | 2025 | Isturisa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $81.42 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $80.38 | 2019-2024 | Evkeeza |
| Amarin Pharma, INC. | $74.88 | 2019-2020 | |
| Ipsen Biopharmaceuticals, INC | $65.92 | 2019 | |
| Beta Bionics, INC. | $63.97 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Cequr Corporation | $60.70 | 2024-2025 | Cequr Simplicity |
| Ferring Pharmaceuticals INC. | $60.60 | 2019 | |
| Antares Pharma, INC. | $58.49 | 2019-2024 | Xyosted |
| Ultragenyx Pharmaceutical INC. | $38.32 | 2022 | |
| Lifescan, INC. | $35.66 | 2020-2022 | |
| Medicure Pharma INC. | $34.39 | 2019 | |
| Averitas Pharma INC. | $32.56 | 2023 | Qutenza |
| Currax Pharmaceuticals LLC | $32.36 | 2022-2025 | Contrave |
| Companion Medical, INC. | $29.17 | 2020 | |
| Ionis Pharmaceuticals, INC. | $28.31 | 2025 | Tryngolza |
| Arbor Pharmaceuticals, INC. | $22.12 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $21.34 | 2019 | |
| Vivus LLC | $19.23 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $18.59 | 2021 | |
| Valeritas, INC. | $16.62 | 2019 | |
| Avvisto Therapeutics, LLC | $16.49 | 2024 | Cycloset |
| Astellas Pharma US INC | $15.26 | 2023 | Veozah |
| Tolmar, INC. | $14.24 | 2024 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$2,026.77 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Isaac Sachmechi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.